Abstract
To evaluate symptom control and tolerability after abrupt conversion from oral extended-release methylphenidate (ER-MPH) to methylphenidate transdermal system (MTS) via a dose-transition schedule in children with attention-deficit/hyperactivity disorder (ADHD). In a 4-week, prospective, multisite, open-label study, 171 children (164 intent-to-treat) with diagnosed ADHD aged 6-12 years abruptly switched from a stable dose of oral ER-MPH to MTS in nominal dosages of 10, 15, 20, and 30 mg using a predefined dose-transition schedule. After the first week on the scheduled dose, the dose was titrated to optimal effect. The primary effectiveness outcome was the change from baseline (while taking ER-MPH) to week 4 in ADHD-Rating Scale-IV (ADHD-RS-IV) total scores. Adverse events (AEs) were assessed throughout the study. Most subjects (58%) remained on the initial MTS dose defined by the dose-transition schedule; 38% increased and 4% decreased their MTS dose for optimization. MTS dose optimization resulted in significantly better ADHD-RS-IV total (mean +/- SD) scores at week 4 than at baseline (9.9 +/- 7.47 vs. 14.1 +/- 7.48; p < 0.0001). The most commonly reported AEs included headache, decreased appetite, insomnia, and upper abdominal...Continue Reading
References
Jul 1, 1990·Journal of the American Academy of Child and Adolescent Psychiatry·R A BarkleyL Smallish
Oct 27, 1998·The Journal of Pediatrics·J BiedermanS V Faraone
Dec 11, 1999·Archives of General Psychiatry
Jun 5, 2001·Pediatrics·W E PelhamG D Morse
Jan 31, 2002·Annual Review of Medicine·Timothy E WilensThomas J Spencer
Feb 9, 2002·Journal of the American Academy of Child and Adolescent Psychiatry·Laurence L GreenhillUNKNOWN American Academy of Child and Adolescent Psychiatry
Nov 20, 2002·Clinical Psychology Review·Mark D Rapport, Catherine Moffitt
May 24, 2005·Journal of the American Academy of Child and Adolescent Psychiatry·William E PelhamGene Morse
Jun 10, 2005·Experimental and Clinical Psychopharmacology·William E PelhamMartin T Hoffman
Jun 14, 2005·Biological Psychiatry·Joseph Biederman
Jul 19, 2005·Lancet·Joseph Biederman, Stephen V Faraone
Dec 3, 2005·Child and Adolescent Psychiatric Clinics of North America·Jefferson B Prince
Dec 14, 2005·CNS Spectrums·David W GoodmanPaul Hodgkins
Feb 17, 2006·Journal of Attention Disorders·James J McGoughEliot Moon
May 4, 2006·The Journal of Clinical Psychiatry·Joseph BiedermanMegan Aleardi
Jun 22, 2007·Journal of the American Academy of Child and Adolescent Psychiatry·Steven Pliszka, UNKNOWN AACAP Work Group on Quality Issues
Nov 3, 2007·Pediatrics·L Eugene ArnoldYaser Ramadan
Mar 4, 2008·The Journal of Clinical Psychiatry·Robert L FindlingRaymond D Pratt
Apr 25, 2008·Journal of the American Academy of Child and Adolescent Psychiatry·Timothy E WilensMichael J Manos
Citations
Sep 9, 2011·European Child & Adolescent Psychiatry·Manfred DöpfnerAribert Rothenberger
Oct 15, 2011·The Patient·Andrew LloydJohn Brazier
Jan 1, 2010·Primary Care Companion to the Journal of Clinical Psychiatry·Erin M WarshawAmy S Paller
Feb 18, 2014·CNS Drugs·Robert L Findling, Steven Dinh
Oct 1, 2013·BMC Psychiatry·David CoghillManfred Doepfner
May 1, 2019·Journal of Child and Adolescent Psychopharmacology·Ronald SteingardMark A Stein
Nov 26, 2011·Expert Review of Clinical Pharmacology·Josephine EliaKarin Borgmann-Winter
May 11, 2018·The Cochrane Database of Systematic Reviews·Ole Jakob StorebøChristian Gluud
May 29, 2019·JAMA Pediatrics·Cellina ChingAlison S Poulton
Apr 13, 2021·CNS Spectrums·Christoph U CorrellMichael Huss